SB17170 Phase 1 Clinical Trial in Solid Tumors
ConditionSolid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorSPARK Biopharma
About this trial
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Eligibility criteria
Qualifiers
A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors.
A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care
A patient with at least one measurable lesion according to the RECIST v1.1 criteria.
A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
Disqualifiers
A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1).
A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug.
A person who needs to take contraindicated drugs or is expected to take them during the study period.
Trial design
Treatments tested in this trial
- SB17170
Treatment groups
50 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov